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The first step in modli lead kinetics dur-
ing pregnancy includes a description of
sequential matenal blood lead (PbB) during
pregnnc and the fatrs contoing it. We
analyzed PbB of Q05 women iving in the
Valley of M ,icofirmweek12 t 36of
pregnacyanPd ain at parturition. We also
useddatafiomal women conItingblood
at any stage of pregnancy to determine
antecedents of PbB. Pregnancies were
uneventful, and offspring were normal.
Although icmnPbBlevelaveged
around7.0gdl (0.34 pmoIl),widz a range
of 1.0-35.5p-gi throughout pn ,
analysis ofvaiace revealed a significant
decrease in ma PbBfiom week 12 to week
20 (1.1 pgdl) andvarious ct res
as in mean PoB from week20 toparturition
(1.6 pg/dl. Regresion analyses confirmed
the po ite l r PbB trend Sm 20 wees
topiiwon-andationalcontutionsof
dietaycaldwn, reprductivehistory,litime
residence in Mexico City, coffee drinking,
and use ofindigenous lead-glaed pottexr.
Although decreasing hematocrit has been
-i, pgtyPbB suggeste toepanfirst-halfprgancPb
decrease, ti. time course of he-mtocrit
decmrese in I pret study didn match
the sequential changes in PhD. While
hemodilution and organ gowth in the firt
halfofp ncy may account for much of
the PbB decrease seen between 12 and 20
weeks, the remaining hemodilution and
acelerate o n gth ofthe last halfof
pregn y do not predict the tead toward
increasingmaternal PbB conc iom
20 weeks to dlivery. Mobilization ofbone
lead, incrd gUt asorption, and s
retention of lead may explain part of the
upwad PbB trendinthesecondhalfofpreg-
nancy. Redution: of lifetime ead posure
may be required to decreae risk offetai
eVposure. K h blood lead, bone lead,
caffeine, cal , pr cy. Envinn Heak
Perspect102:8764880 (1994)
The period of fetal growth is often the
stage of development at which the organ-
ism is most sensitive to toxic agents.
However, we cannot directly measure fetal
exposure during pregnancy in human
research studies. Maternal measurements
are the only exposure indices ethically
available. To infer fetal lead exposure from
maternal measurements of blood lead
(PbB), we need a detailed understanding of
both the factors influencing and the kinet-
ics of maternal-fetal lead transfer. Given
the strong interest in the effects oflow-level
lead on child development, we know sur-
prisingly little of even the time course of
maternal PbB levels during pregnancy.
Cross-sectional studies of groups of
women at different stages of pregnancy
present conflicting results (1-3), and the
design is inadequate to study serial changes
of lead during pregnancy. Case studies
with serial measurements of PbB in preg-
nant women are interesting (4-6), but
these are usually ofwomen suffering frank
lead intoxication.
The only detailed work prospectively
studying PbB in pregnant women is that of
Barltrop (7), published over 25 years ago.
He examined serial PbB levels in 12
women from as early as the first trimester
ofpregnancy to delivery and could discern
no recognizable pattern.
We present here serial PbB measure-
ments from week 12 to delivery from 105
women with uneventful pregnancies and
deliveries from the Mexico City
Prospective Lead Study. Our aim is to
characterize PbB changes during normal
pregnancy and to investigate some of the
many factors, both environmental and
physiological, that influence alterations in
PbB as a necessary first step in understand-
ing the dynamics oflead metabolism dur-
ing pregnancy.
Methods
Subject. Outpatient staffscreened women
arriving at the outpatient service of the
National Institute of Perinatology around
or before week 12 ofpregnancy as calculated
from the date oflast menses. As the insti-
tute is a service, training, and research cen-
ter for treating reproductive problems,
including high-risk pregnancies, pregnant
women not presenting a risk factor are
normally referred to other treatment facili-
ties. Between March 1987 and June 1992,
however, pregnant women not meeting the
institute's admission requirements were
referred to the lead study's physician for
further screening.
Apriori exclusion criteria for the study
were: 1) younger than 15, older than 42;
2) active diabetes, German measles, hepati-
tis, or toxoplasmosis, as determined by lab-
oratory test, 3) habitual use of alcohol or
drugs, 4) use of prescription medications,
5) hypertension controlled with medica-
tion, 6) active psychosis. Women not
excluded by these criteriawere informed of
the purpose of the study and the proce-
dures involved. They read, or were read, a
statement of informed consent approved
by the institutional review board, and
signed it.
A total of 532 women passed the
exclusion criteria and were enrolled in the
study. Ofthis total, 30 never arrived at the
project office for their first or following
appointments. One case developed hypo-
glycemia and 27 developed conditions
described by the above exclusion criteria
during their pregnancy; 22 spontaneously
aborted, and 16 were stillbirths. We will
report these data elsewhere. The exclusion
ofthese subjects left 436 participants.
Some of the remaining women gave
birth to babies meeting the following a
prioriexclusion criteria, and these 22 preg-
nancies were also removed from the pre-
sent data set: 1) birth weight under 2000 g,
2) gestation age under 36 weeks, 3) 5-min
Apgar score under 6, 4) multiple birth,
and 5) major congenital anomaly. An
additional 41 babies suffered from hyper-
bilirubinemia, high lead level [one baby
was born with a cord level of 69 pg/dl
(3.33 pmol/l); see Rothenberg et al. (6)
for description of this case], minor con-
genital anomaly, severe infection, birth
trauma, asphyxia, respiratory difficulty, or
early infant death, and these cases were
also excluded from the data set.
Table 1 summarizes data on 159
patients who were excluded or who
dropped out of the study and compares
them to 373 patients retained in the study.
Excluded patients were significantly older,
had more pregnancies and abortions, and
gave birth to lower birth-weight and lower
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Table 1. Comparison of excluded and drop-out
cases with retained sample.
Parameter"
Age of mother (years)
Pregnancies
Abortions
Birth weight (g)
Gestation age (weeks)
Socioeconomic status (1-9)
Lead level, 12weeks (pg/dl)b
Lead level, 20weeks (pg/dl)
Lead level, delivery(pg/dl)
ExcludedI
(N= 159)
29.8t
2.75*
0.84**
2697t
37.6t
3.8
7.7
6.3
8.3
Retained
(N= 373)
27.5
2.51
0.63
3186
39.9
3.7
7.7
6.8
8.3
aSignificance measured by t-test except for
socioeconomic status, for which Mann-Whitney
U was used. *p<0.10. **p<0.05. tp<0.001.
bConversion factor for blood lead, 10.0 pg/dl = 0.48
pmol/l.
gestation-age babies than included moth-
ers. The latter two differences were not
unexpected, as low birth weight and gesta-
tion age were part ofthe exclusion criteria.
The two groups did not differ according to
marital status, socioeconomic level, or,
where available, PbB.
The exclusion criteria ensured basically
healthy pregnancies and deliveries in the
sample. The sample was predominantly
urban or suburban, all living within the
Valley ofMexico during their pregnancies,
oflower socioeconomic status, small fami-
lies, mostly married, and with low alcohol
and cigarette use. Socioeconomic status
was calculated as the unweighted mean of
three ordinal scales measuring head offam-
ily's education and occupation and total
income, the latter determined by multiples
ofminimum wage current at time ofmea-
surement. The 1980 national census indi-
cated that just under 8% of the national
population was ofpure indigenous ancestry
but gave no other ethnic or racial break-
down. We made no attempt at racial or
ethnic classification ofthe sample.
Only 105 subjects in the sample con-
tributed 5 analyzable blood samples, one at
each period of the pregnancy and one at
delivery. There were no significant differ-
ences between the group with complete
PbB data and the remainder ofthe sample
on the demographic, socioeconomic, and
reproductive history variables mentioned
above.
Blood Sampling. Blood samples were
drawn by venipuncture at 8-week intervals
(± 2 weeks) from week 12 to week 36 of
pregnancy and again from the mother
within 15 min of delivery. An umbilical
cord blood sample was also drawn (data
reported elsewhere). In all cases venipunc-
ture sites were thoroughly cleaned with
antiseptic soap, finishing with unidirec-
tional wipes with prepared alcohol-saturat-
ed pads. At least 2 ml ofblood was drawn
for the PbB samples and stored in purple-
top Vacutainers (Becton-Dickinson) with
EDTA. At the 12 to 36 week appoint-
ments, blood was also drawn for clinical
blood workup. Vacutainers were stored at
4°C until shipping.
BloodLeadAnalysis. The Vacutainers
were shipped to Environmental Sciences
Associates (ESA) Laboratories, Inc.
(Bedford, Massachusetts) for analysis. ESA
Laboratories is one ofthe reference labora-
tories for the Centers for Disease Control
Blood Lead Proficiency Testing Program
and is a participant in the New York State
Department ofControl Program.
All samples were analyzed in duplicate
by the method ofanodic stripping voltam-
metry. Samples with mean duplicate values
below 5 pg/dl (0.24 pmol/l) were reana-
lyzed in duplicate by atomic absorption
spectrometry with graphite furnace, and
the previously analyzed values were dis-
carded. Mean values ofthe duplicate analy-
ses were used as data. In cases where mean
values were below 1 pg/dl (0.05 pmol/l),
values were rounded up to 1 pg/dl (0.05
pmol/l).
Comparison of ESA Laboratories per-
formance with the other five CDC refer-
ence labs over the study period showed
that ESA Laboratories reported an average
lead value 0.7 pg/dl (0.03 pmol/l) lower
for the low and mid-range samples (usually
covering the lead range found in our sam-
ple). This included 3 different months
when ESA Laboratories results exceeded
the control limit (Hotelling T-square, ax =
0.05) based on the other five laboratories
on one or more ofthe three CDC samples.
None ofour samples was analyzed in those
3 months. Mean difference ofthe duplicate
values of all maternal samples from the
study (N = 1913) was 1.2 pg/dl (0.06
pmol/l) with only 4.0% of the samples
exceeding a difference of 3.0 pg/dl (0.14
pmol/l). For samples with mean lead level
less than 5.0 pg/dl (0.24 pmol/l), i.e., those
analyzed with atomic absorption spectrom-
etry, the comparable values were 0.9 pg/dl
(0.04 pmol/l) and 3.3%. Use of mean
duplicate values in the statistical analyses
reduced reliability error.
StatistiealAnalysis. Statistical analysis
was performed separately on the 105 sub-
jects with complete PbB data through the
pregnancy and on the entire data set. The
goal ofthe analysis was to determine signif-
icant changes and significant trends in lead
during the pregnancy and to account for
intrinsic and extrinsic variables associated
with lead at each stage ofpregnancy.
All PbB measurements were converted
to their natural logarithmic values in an
effort to normalize the positively skewed
lead distributions. Nevertheless, trans-
formed distributions were slightly tail
heavy on the low side of the distribution,
likely due to adopting the strategy of
rounding all measured lead levels below 1
pg/dl up to 1.
A repeated-measures fixed-effects
model ANOVA was used to assess signifi-
cant changes in maternal lead during preg-
nancy on the group with complete data,
with post-hoc comparisons performed
using least significant differences. We used
linear and multiple linear regression mod-
els to calculate trends in maternal lead dur-
ing the pregnancy.
To assess the variables that were signifi-
cantly associated with lead at each time
period during pregnancy, we performed a
series of univariate and bivariate statistical
tests of control and confounding variables
against natural log-transformed lead using
the entire available data set. Variables sig-
nificantly associated with maternal lead
(p<0.10) at each period in pregnancy were
retained for possible entry in a forward,
stepwise multiple regression with backward
elimination (entry and elimination criteria
were p<O.O0 and p>O.0, respectively).
This technique assured that multicollinear-
ity was minimized and that the statistical
effect of each variable retained in the
model against lead was independent ofthe
other variables. Final multiple regression
models maximized variance of lead
accounted for at each period in the preg-
nancy. Statgraphics Plus (Manugistics,
Rockville, Maryland) and SPSS (Chicago)
were used for data analysis.
Results
Figure 1 shows geometric mean PbB at
each measurement period in the pregnancy
for the group with complete lead data and
the group with one or more missing data
points. Although there was a tendency for
the incomplete group to have higher lead
levels than the complete group, t-tests for
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Figure 1. Plot of time course of maternal blood
lead (geometric mean and SEM) during pregnancy
for subjects with complete and incomplete data.
Incomplete data are offset on the X-axis for clari-
ty. Upward trend of complete subjects from 20
weeks to term is significant. Ranges of horizontal
lines above the data indicate significant compar-
isons using least significant differences post-hoc
test, with indicated probabilities. Conversion fac-
torfor blood lead is 10.0 pg/dl =0.48 pmoVI.
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877Table 2. Multiple regression model fitting results for blood lead (PbB) levels at differenttimesa
Independent variable Coefficient SE p
PbB, 12 weeks
Constant 2.749 0.275
Canned fruit, frequency of consumption 0.136 0.064 <0.05
Home remedies, last3 months 0.205 0.089 <0.05
Birthplace, (Mexico City) 0.236 0.100 <0.05
Low-temperature ceramic ware use 0.160 0.080 <0.05
I2 (adjusted) = 0.056 SE = 0.630 MAE = 0.472 N= 261
PbB, 20weeks
Constant 2.532 0.187
Coffee 0.174 0.091 <0.10
Low-temperature ceramic ware use 0.368 0.081 <0.001
Date of PbB sampling (months) 0.005 0.002 <0.01
#? (adjusted) = 0.094 SE = 0.674 MAE = 0.494 N= 296
PbB, 28 weeks
Constant 3.204 0.334
Pregnancies (number) -0.097 0.034 <0.01
Soft drinks, frequency of consumption 0.060 0.031 <0.10
Canned milk, frequency of consumption 0.117 0.033 <0.001
Coffee drinking 0.296 0.097 <0.01
Birthplace (Mexico City) 0.399 0.105 <0.001
Low-temperature ceramic ware use 0.280 0.081 <0.001
Complications in previous pregnancies 0.201 0.093 <0.05
Date of PbB sampling (months) 0.006 0.002 <0.01
i2 (adjusted) = 0.209 SE = 0.674 MAE = 0.514 N= 288
PbB, 36 weeks
Constant 2.902 0.294
Abortions (number) -0.188 0.045 <0.001
Alcohol (quantity) 0.138 0.071 <0.10
Milk, frequency of consumption -0.108 0.043 <0.05
Softdrinks, frequency of consumption 0.057 0.031 <0.10
Complications in previous pregnancies 0.166 0.084 <0.05
Low-temperature ceramic ware use 0.435 0.083 <0.001
Date of PbB sampling (months) 0.007 0.002 <0.001
#? (adjusted) = 0.212 SE = 0.635 MAE = 0.489 N= 253
PbB at delivery
Constant 2.896 0.231
Abortions (number) -0.100 0.044 <0.05
Family members (number) -0.182 0.076 <0.05
Low-temperature ceramic ware use 0.293 0.085 <0.001
Birthplace (Mexico City) 0.214 0.109 <0.05
Date of PbB sampling (months) 0.007 0.002 <0.001
# (adjusted) = 0.121 SE = 0.687 MAE = 0.515 N= 281
MAE, mean absolute error.
aConversion factor for blood lead, 10.0 pg/dl = 0.48 pmol/l. Coefficients are in units of natural logarithm
PbB (pg/dl).
Table 3. Multiple regression model: natural logarithm of maternal lead (pg/dl), 20weekstoterma
Independent variable Coefficient SE p
Constant 2.558 0.290
Weeks of pregnancy 0.012 0.004 <0.01
Date of PbB sampling (months) 0.005 0.002 <0.01
Low-temperature ceramic ware use 0.203 0.074 <0.01
Birthplace (Mexico City) 0.174 0.089 <0.05
Coffee consumption 0.237 0.074 <0.01
Abortions (number) -0.083 0.032 <0.01
Milk,frequency of consumption -0.058 0.034 <0.10
i2 (adjusted) = 0.114 SE = 0.665 MAE = 0.513 N= 420
MAE, mean absolute error.
aConversion factor for blood lead, 10.0 pg/dl = 0.48 pmo
independent samples yielded an insignifi-
cant difference (using natural log-trans-
formed data) between groups (p>0.10) for
each time point during pregnancy.
A repeated-measures ANOVA on data
from the complete group using the log-
transformed PbB values produced a signifi-
cant weeks-of-pregnancy effect [F(4,524) =
2.69, p = 0.03]. A least significant differ-
ence post-hoc analysis (see ranges in Fig. 1)
showed a significant drop in PbB from
week 12 to week 20 and various significant
increases in PbB from week 20 through
delivery. Using data from week 20 through
delivery, an analysis for linear trend con-
firmed the significant PbB rise through this
period ofpregnancy [F(1,419) = 6.44, p =
0.01].
Multiple regression models ofmaternal
lead at each 8-week period of pregnancy
and at delivery were constructed using data
from all subjects (Table 2). Dietary factors
such as use of canned foods, soft drinks,
coffee, and alcohol were associated with
increased maternal lead during various
periods of pregnancy, while use of lead-
glazed ceramic ware was associated with
increased maternal lead throughout all the
pregnancy. Increased milk consumption
was associated with decreased maternal
lead late in the third trimester. Birthplace
was a significant predictor ofmaternal lead
at various times during pregnancy; mothers
born in the Valley of Mexico had higher
lead than those born outside the valley.
Reproductive history, especially history of
abortions or gravidity, which were associat-
ed with decreased maternal lead, were
prominent in the last trimester. Later date
ofblood sampling during the study period
was significantly associated with increased
PbB in the last halfofpregnancy.
Table 3 shows the trend from 20 weeks
of pregnancy through delivery for the
group with complete data corrected for sig-
nificant predictors ofmaternal PbB at two
or more time points in pregnancy discov-
ered through the multiple regression mod-
eling. Despite correcting blood lead values
by these important determinants of blood
lead during pregnancy in the multiple
regression analysis, weeks of pregnancy in
the last half of pregnancy was still signifi-
cantly associated with increased maternal
PbB.
Figure 2 shows maternal hematocrit
from weeks 12 to 36 of pregnancy.
Maternal hematocrit decreased from weeks
12 to 28 and remained unchanged at 36
weeks. Maternal PbB and hematocrit did
not follow the same time course from week
12 to week 36 ofpregnancy.
Discussion
Dietary sources of lead, especially promi-
nent in the study population, were associ-
ated with increased PbB during pregnancy.
Mexico has a nearly 500-year history of
using lead-glazed pottery for cooking, serv-
ing, and storing food and drink. Although
lead in domestic articles was recognized in
Mexico as a source of lead poisoning in
children nearly two centuries ago (8), and
despite repeated notice to public health
authorities regarding lead in ceramic ware
(9-11), little has been done to remedy the
problem until recently. As a result, the
more than 40% of our sample reporting
use oflead-glazed pottery showed elevated
PbB during the last 28 weeks ofpregnancy.
Canned foods using lead-soldered
seams were common in the Mexican mar-
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Figure 2. Time course of mean maternal hemat-
ocrit and mean maternal weight gain during
pregnancy. Error bars are standard error of the
mean. Weight gain was not measured at 12
weeks, and hematocrit was not measured at
delivery.
ketplace until 1993, when seamless or
welded-seam cans replaced all but a small
fraction, represented by imported foods.
Canned foods, associated with increased
maternal PbB, were also related to higher
lead in children born to mothers partici-
pating in this study in a preliminary report
(12). As existing stocks of lead-soldered
cans are reduced, we expect the contribu-
tion ofthis source to the national lead load
to disappear.
All mothers entering the study were
given basic information on the major
sources oflead and on the effects oflead on
the fetus and young child and were urged
to discontinue habits leading to increased
lead intake. As we only assessed food
preparation habits and food use at the
beginning of the study period, we were
unable to determine the extent that these
patterns changed during the pregnancy and
thus may have contributed to the alter-
ations of PbB measured. However, to the
extent that the educational efforts were
successful in reducing lead intake during
pregnancy, the reported increases in lead in
the last 20 weeks of pregnancy would be
underestimated.
Investigators using a cross-sectional
design have reported a drop in maternal
PbB during periods roughly corresponding
to our 12- to 20-week interval (3). The
decrease observed during this period has
usually been attributed to increased fluid
volume, measured by hematocrit, during
the first halfofpregnancy. The increase in
plasma volume during pregnancy is well
documented and amounts to an average of
1200 ml in the first 34 weeks ofpregnancy
(13). The expansion of blood volume is
greatest in the second trimester, but the
increased erythrocyte production during
pregnancy does not keep pace with
increased fluid volume, resulting in
decreased hematocrit.
We observed the expected decrease in
hematocrit in the first halfofpregnancy as
well. However, hematocrit decreased every
8 weeks from week 12 to week 28 and then
remained unchanged at 36 weeks in our
study. The time course of the hematocrit
change across pregnancy did not corre-
spond to the time course of PbB change.
Furthermore, hematocrit-corrected PbB
values followed the same time course
throughout the pregnancy as non-hemat-
ocrit-corrected PbB, and hematocrit was
not statistically associated with lead in the
multivariate models. Although hematocrit
changes in the first 20 weeks ofpregnancy
could explain some of the observed PbB
decrease between 12 and 20 weeks,
decreased hematocrit cannot account for
the observed PbB increase thereafter.
Growth in other organs can also serve
as a sink for circulating maternal PbB in
the first 20 weeks ofpregnancy. The fetus
has attained 10% of its term weight, the
placenta over 25%, the uterus 30%, the
mammaries over 40%, with total weight
gain in the mother around one-third that
experienced at the end of pregnancy (14).
Almost all ofthe increase in cardiac output
and in glomerular filtration rate is achieved
by 20 weeks of pregnancy (15,16), and
though never reported, excretion of lead
during the first halfofpregnancy might be
enhanced. Assuming unchanging lead
intake, the combination of hemodilution,
increased weight of organs and enhanced
metabolic activity could account for much
of the observed decrease in whole PbB
between 12 and 20 weeks ofpregnancy.
Although the time course of these fac-
tors is correlated with the decrease in PbB
in the first 20 weeks of pregnancy, the
majority of the change in fetal and mater-
nal organ size occurs after 20 weeks (see
Figure 2 for weight gain in our subjects).
Other factors must intervene to produce
the measured increase in blood lead in the
last half of pregnancy despite increasing
hemodilution and organ weights.
Various physiological changes during
pregnancy may account for increased PbB
in the last half of pregnancy. Accelerated
absorption of dietary lead and decreased
elimination oflead from the body, perhaps
following the calcium conservation strate-
gies of late pregnancy (17), and release of
bone lead may all operate to yield the
observed pattern oflead during pregnancy.
Although lead in blood and other soft
tissues has a mean-life after single dose of
35 days (18), the half-times oflead in bone
are 5-20 years (19), allowing it to accumu-
late over the life of an individual. Lead
accumulates in bone by replacing calcium
in the apatite. Its flow from blood to bone
is mediated by osteoblast activity, whereas
the principal return from bone to blood is
related to osteoclast activity (20). Saltzman
(21) estimated that at age 20, about 78%
of the total lead in the body of humans
resides in bone, rising to 96% at age 80.
Although normally lead in bone is nearly
immobile, some processes that increase
bone turnover, notably pregnancy, may
increase mobilization of lead from bone
(22-26).
Most ofthe accumulation offetal calci-
um occurs in the last trimester, coinciding
with the mineralization of the fetal skele-
ton. Parathyroid hormone responds to
changes in plasma calcium, decreasing dur-
ing the first trimester of pregnancy and
increasing thereafter (17,27). Increased
parathyroid hormone is associated with
increased bone resorption, increased
intestinal absorption of calcium, and kid-
ney reabsorption of calcium, likely in
response to fetal need, and it stimulates
renal biosynthesis of 1,25(OH)2D, which
mobilizes calcium from the bone (28).
Processes that mobilize calcium from bone
during pregnancy could also mobilize lead
from bone.
Several ofour findings suggest that the
increasing PbB found in the last half of
pregnancy derives in part from maternal
bone lead in addition to increased gut
absorption. First, the timing ofthe increase
in the last halfofpregnancy coincides with
increased fetal need for and increased
maternal provision of calcium (29). If
some of the additional fetal calcium
requirement is supplied from maternal
bone, mothers with high bone loads oflead
may transfer more lead to the bloodstream
with the calcium.
Second, mothers in our study who had
low milk intake, our measure of dietary
calcium, had higher PbB levels late in preg-
nancy. Calcium-deficient diets are associat-
ed with increased intestinal absorption of
dietary lead (28). But lead may also be
provided from the bone during times of
high calcium stress in pregnant women
with calcium-deficient diets (24).
Third, mothers born and living most of
their lives in Mexico City had higher late
pregnancy PbB than mothers born outside
ofthe city. Mexico City has had historical-
ly high air lead levels, due primarily to the
use of heavily leaded gasoline (30). These
levels peaked in the early 1980s and have
been dropping since then as programmed
gasoline lead reductions have been imple-
mented. Mothers born, growing up, and
living in Mexico City all their lives may
have higher lifetime exposures to lead than
mothers born elsewhere in the country,
and this would be reflected in higher bone
lead.
Fourth, mothers in our study with
more abortions or more prior pregnancies
had lower PbB levels in the last trimester of
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pregnancy. If the fetus transports substan-
tial maternal lead from the mother's body,
lowering body (bone) stores oflead in sub-
sequent pregnancies, multigravid women
should have lower PbB. Indeed, lower cord
PbB has been reported before in multi-
gravid women (31).
Fifth, maternal coffee consumption was
associated with increased PbB. This rela-
tionship has been reported before in a
study investigating cord PbB, though it
was not discussed (31). Although drinking
coffee prepared and served in lead-glazed
ceramic ware is common in Mexico, the
association between coffee drinking and
increased lead is independent of the effect
ofuse oflead-glazed ceramic ware on PbB,
as noted in the multiple regression analyses
(Table 3). Caffeine intake is associated
with increased calcium excretion in women
(32,33), likely due to its effect on renal
reabsorption (34). There are no data
reported in the literature regarding the
effect of caffeine on lead excretion. As in
women with reduced milk intake, the
increase in PbB with coffee use might arise
from compensatory increased gut absorp-
tion of lead. However, the still-disputed
link between caffeine intake and bone loss
in post-menopausal women (35) also sug-
gests the possibility that some of the
increased PbB related to coffee drinking
seen in this study may derive from bone
lead release in women whose calcium bal-
ance is further compromised by caffeine
during pregnancy.
Since no measurements of bone, envi-
ronmental, or dietary lead were made, the
sources for maternal lead changes during
pregnancy suggested by the models can
only be considered tentative. Although the
increased PbB in the last halfofpregnancy
is small, on the average about 1.6 pg/dl
(0.07 mol/l; approximately 20%) from 20
weeks to parturition, this increase is found
in the face of hemodynamic, metabolic,
and organ size changes, all ofwhich act to
reduce maternal PbB concentration. Thus
the measured increase indicates that, what-
ever the source, the amount of lead put
into circulation in the last halfofpregnan-
cy may be substantial and physiologically
significant.
The preceding results suggest that
women with higher lifetime exposures, and
thus more bone lead, and calcium-deficient
women may have higher circulating lead
levels during the second half of pregnancy
with consequent increased exposure to the
fetus. The results imply that to gain maxi-
mum public health savings through lead-
reduction programs, our goal should be to
reduce lead-exposure ofwomen at the ear-
liest age possible and maintain the reduc-
tion through their reproductive years. We
might expect a time lag of a generation or
more before the benefits of reduced envi-
ronmental lead are fully passed on to the
fetus.
Many kinetic models oflead in organ-
isms have been developed, though none yet
treats lead during pregnancy in humans.
Any valid kinetic model of the
maternal-fetal PbB system must not only
account for the decrease in maternal PbB
in the first 20 weeks ofpregnancy, it must
also account for the measured increase in
the second 20 weeks.
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